Revolution Medicines (RVMD) Free Cash Flow (2019 - 2026)

Revolution Medicines' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$355.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 79.98% year-over-year to -$355.0 million; the TTM figure through Mar 2026 stood at -$1.1 billion (down 75.49% YoY), while the FY2025 annual figure was -$899.6 million, down 58.45% from the prior year.
• Free Cash Flow was -$355.0 million for Q1 2026 at Revolution Medicines, down from -$274.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$55.3 million in Q4 2022 to a low of -$355.0 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$141.3 million across 5 years, with a median of -$131.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow declined 12.87% in 2023, then slumped 153.24% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$55.3 million in 2022, then sank by 120.47% to -$121.8 million in 2023, then decreased by 14.5% to -$139.5 million in 2024, then sank by 96.89% to -$274.7 million in 2025, then retreated by 29.22% to -$355.0 million in 2026.
• The last three Free Cash Flow figures came in at -$355.0 million (Q1 2026), -$274.7 million (Q4 2025), and -$198.0 million (Q3 2025), per Business Quant data.